BRCA2 and breast carcinoma: For example, breast cancer cells with mutations in the BRCA1 and BRCA2 are sensitive to inhibition of poly [ADP-ribose] polymerase (PARP1), whereas inhibition of PARP1 has little influence on survival and proliferation of normal cells with WT BRCA (58,59).